Home
>
National Drug Code (NDC)
>
LEXIVA
LEXIVA - 49702-207-18 - (fosamprenavir calcium)
Drug Information of LEXIVA
| Product NDC: | 49702-207 |
| Proprietary Name: | LEXIVA |
| Non Proprietary Name: | fosamprenavir calcium |
| Active Ingredient(s): | 700 mg/1 & nbsp; fosamprenavir calcium |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of LEXIVA
| Product NDC: | 49702-207 |
| Labeler Name: | ViiV Healthcare Company |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA021548 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20101004 |
Package Information of LEXIVA
| Package NDC: | 49702-207-18 |
| Package Description: | 60 TABLET, FILM COATED in 1 BOTTLE (49702-207-18) |
NDC Information of LEXIVA
| NDC Code | 49702-207-18 |
| Proprietary Name | LEXIVA |
| Package Description | 60 TABLET, FILM COATED in 1 BOTTLE (49702-207-18) |
| Product NDC | 49702-207 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | fosamprenavir calcium |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20101004 |
| Marketing Category Name | NDA |
| Labeler Name | ViiV Healthcare Company |
| Substance Name | FOSAMPRENAVIR CALCIUM |
| Strength Number | 700 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC],Cytochrome P450 3A4 Inhibitors [MoA] |
